A carregar...
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the goal and expectation for most patients. More recently, treatment-free remission (TFR) has entered mainstream pract...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6246017/ https://ncbi.nlm.nih.gov/pubmed/30504306 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|